Table 1.
CD47 antagonists currently entering clinical trials for treatment of lymphomas
| Drug Name |
Other Name | Companies | Target-based Actions | Drug Classification | Indications | US Highest Phase | Chinese Highest Phase | NCT | CTR |
|---|---|---|---|---|---|---|---|---|---|
| CC-90002 | INBRX-103 | Bristol-Myers Squibb Company | CD47 antagonist | anti-CD47 monoclonal antibody | Non-Hodgkin lymphoma | Phase I | / | NCT02641002 | / |
| GenSci-059 | GenSci-059 | GeneScience Pharmaceuticals Co Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | / | NCT05221385 | / |
| IMC-002 | 3D-197 | ImmuneOncia Therapeutics LLC | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | / | NCT04306224 | / |
| Lemzoparlimab | TJ011133; TJC4 | I-Mab Bio-Tech (Tianjin) Co., Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | / | NCT03934814 | / |
| CD20 positive lymphoma | / | Phase I | / | CTR20210313 | |||||
| Letaplimab | IBI-188 | Innovent Biologics Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | Phase I | NCT03717103, NCT03763149, NCT04861948 | CTR20182140 |
| Ligufalimab | AK117 | Akeso Biopharma Inc | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | Phase I | NCT04728334, NCT04349969 | CTR20202684 |
| Magrolimab | Hu5F9-G4 | Gilead Sciences | CD47 antagonist | anti-CD47 monoclonal antibody | Non-Hodgkin lymphoma | Phase II | / | / | |
| Classic Hodgkin lymphoma | Phase II | / | NCT04788043 | / | |||||
| T-Cell lymphoma | Phase II | / | NCT04541017 | / | |||||
| MIL-95 | CM-312 | KeyMed Biosciences Co Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | Phase I | NCT04651348 | CTR20201108 |
| SHR-1603 | SHR-1603 | Jiangsu Hengrui Medicine Co Ltd | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | Phase I | NCT03722186 | CTR20181964 |
| ZL-1201 | ZL-1201 | Zai Lab Limited | CD47 antagonist | anti-CD47 monoclonal antibody | Lymphoma | Phase I | Phase I | NCT04257617 | CTR20210973 |
| BAT-7104 | BAT-7101 | Bio-Thera Solutions Ltd | CD47 antagonist; Programmed cell death ligand 1 inhibitor | bispecific antibody | Lymphoma | Phase I | / | CTR20220098 | |
| HX-009 | HX-009–5 | HanX Biopharmaceuticals Inc | CD47 antagonist; Programmed cell death protein 1 inhibitor | bispecific antibody | Lymphoma | Phase II | Phase II | NCT05189093 | CTR20213391 |
| IBI-322 | IBI-322 | Innovent Biologics Inc | CD47 antagonist; Programmed cell death ligand 1 inhibitor | bispecific antibody | Lymphoma | Phase I | / | NCT04338659 | / |
| IMM-0306 | IMM-0306 | ImmuneOnco Biopharm Co Ltd | B-lymphocyte antigen CD20 modulator; CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | bispecific antibody | CD20-positive B-cell non-Hodgkin's lymphoma | Phase I | / | NCT04746131 | CTR20192612 |
| JMT-601 | CPO-107 | Shanghai JMT-Bio Inc | B-lymphocyte antigen CD20 modulator; CD47 antagonist | bispecific antibody | CD20 positive B-cell non-Hodgkin's lymphoma | Phase II | Phase II | NCT04853329 | CTR20211365 |
| SG-12473 | SG-12473 | Hangzhou Sumgen Biotechnology Co Ltd | CD47 antagonist; Programmed cell death ligand 1 inhibitor | bispecific antibody | Lymphoma | / | Phase I | / | CTR20211029 |
| TG-1801 | NI-1701 | TG Therapeutics Inc | B-lymphocyte antigen CD19 modulator; CD47 antagonist; Immunoglobulin Fc receptor agonist | bispecific antibody | B-Cell Lymphoma | Phase I | / | NCT03804996, NCT04806035 | / |
| XL-114 | AU-341; AU7R-104; AUR-104 | Exelixis Inc | Bcl-10 protein modulator; CD47 antagonist; Caspase recruitment domain protein 11 modulator; Epidermal fatty acid binding protein inhibitor | bispecific antibody | Non-Hodgkin lymphoma | Phase I | / | NCT05144347 | / |
| Evorpacept | ALX-148 | ALX Oncology | SIRPα-Fc fusion protein,SIRPα/CD47 blocker | SIRPα/Fc fusion protein antibody | B-cell Non-Hodgkin Lymphoma | Phase II | / | NCT05025800, NCT03013218 | / |
| IMM-01 | IMM-01 | ImmuneOnco Biopharm Co Ltd | CD47 antagonist | SIRPα/Fc fusion protein antibody | Hodgkin's lymphoma, B-cell non-Hodgkin lymphoma; NK/T-cell lymphoma | / | Phase II | / | CTR20212227 |
| IMM-01 | IMM-01 | ImmuneOnco Biopharm Co Ltd | CD47 antagonist | SIRPα/Fc fusion protein antibody | Lymphoma | / | Phase II | / | CTR20191531 |
| TTI-621 | TTI-621 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Mycosis fungoides | Phase I | / | NCT02890368 | / |
| TTI-622 | TTI-622 | Trillium Therapeutics Inc | CD47 antagonist; Immunoglobulin gamma Fc receptor agonist | SIRPα/Fc fusion protein antibody | Lymphoma | Phase I | / | NCT03530683 | / |
| RRx-001 | RRx-001 | EpiCentrx Inc | CD47 antagonist; DNA methyltransferase inhibitor; Epigen modulator; Programmed cell death ligand 1 inhibitor; Tyrosine phosphatase substrate 1 inhibitor | small-molecule inhibitor | Lymphoma | Phase I | / | NCT01359982, NCT02096341, NCT02518958 | / |